Eurizon SLJ Capital Ltd Takes $630,000 Position in Eli Lilly and Company $LLY

Eurizon SLJ Capital Ltd bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 586 shares of the company’s stock, valued at approximately $630,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Coyle Financial Counsel LLC grew its holdings in shares of Eli Lilly and Company by 64.5% during the 4th quarter. Coyle Financial Counsel LLC now owns 482 shares of the company’s stock valued at $518,000 after purchasing an additional 189 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $568,775,000. Hillsdale Investment Management Inc. grew its holdings in shares of Eli Lilly and Company by 56.2% during the 4th quarter. Hillsdale Investment Management Inc. now owns 5,854 shares of the company’s stock valued at $6,291,000 after purchasing an additional 2,107 shares during the last quarter. Zhang Financial LLC grew its holdings in shares of Eli Lilly and Company by 2.0% during the 4th quarter. Zhang Financial LLC now owns 2,660 shares of the company’s stock valued at $2,858,000 after purchasing an additional 53 shares during the last quarter. Finally, Fideuram Asset Management Ireland dac bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $16,587,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Leerink Partners set a $1,119.00 target price on shares of Eli Lilly and Company in a report on Tuesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,105.37 on Friday. The firm has a market cap of $1.04 trillion, a PE ratio of 39.27, a price-to-earnings-growth ratio of 1.23 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,149.10. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company’s fifty day simple moving average is $955.92 and its two-hundred day simple moving average is $1,009.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, meaning all three major PBMs now cover Lilly’s full obesity portfolio. That should expand access for millions of patients and strengthen Lilly’s market share versus Novo Nordisk. Article Title
• Positive Sentiment: Reuters also reported that Mounjaro outperformed other GLP-1 drugs in some type 2 diabetes patients, reinforcing Lilly’s competitive edge in the diabetes and obesity markets. Article Title
• Positive Sentiment: Wall Street is also reacting to Lilly’s broader pipeline momentum, including positive Phase 1b data for Verve-102 and progress in olomorasib, which supports the view that Lilly is more than just a weight-loss story. Article Title
• Positive Sentiment: Lilly announced a major push into vaccines, including the planned acquisition of Curevo Vaccine for $1.5 billion and other vaccine-developer deals, signaling a new long-term growth avenue outside cardiometabolic care. Article Title
• Positive Sentiment: Analyst and media coverage has been upbeat, with commentary highlighting Lilly’s “brilliant management,” record valuation, and strong pipeline, which can help sustain momentum in the stock. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.